Syndax Pharmaceuticals Intrinsic Stock Value – Syndax Pharmaceuticals Sees Loss Despite Market Gains, Here’s What You Should Know

Trending News 🌧️

Syndax Pharmaceuticals Intrinsic Stock Value – Syndax Pharmaceuticals ($NASDAQ:SNDX), a biopharmaceutical company based in the United States, saw a dip of $0.45 in its stock price at the close of trading despite the market’s overall gains. This loss was unexpected considering the market’s positive performance. Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of innovative combination therapies in the field of cancer. The company has a wide range of clinical programs that are being developed with the aim of treating cancer and other diseases. Its pipeline includes drugs for the treatment of breast cancer, melanoma, and multiple myeloma. Syndax Pharmaceuticals has a strong track record of developing novel treatments. The company has successfully developed and launched two drugs, Entinostat and Selinexor, which have been approved by the US Food and Drug Administration (FDA). Its third drug, Vicinium, is currently in Phase III clinical trials and is expected to be approved soon. Syndax Pharmaceuticals is also engaged in strategic collaborations with other industry leaders such as Pfizer and Merck & Co., which will help it to accelerate the development of its pipeline drugs.

In addition, the company is focusing on expanding its portfolio by investing in new technologies and acquiring promising assets. Despite the current market losses, analysts remain optimistic about the future performance of Syndax Pharmaceuticals. The company has a strong research and development team, which is working on innovative combination therapies that could transform the cancer treatment landscape. With its promising pipeline, strategic partnerships, and focus on expanding its portfolio, Syndax Pharmaceuticals is well positioned to capitalize on opportunities and generate long-term value for its shareholders.

Price History

Syndax Pharmaceuticals experienced a loss despite the market gains. At the time of writing, media sentiment was mostly positive surrounding the company. On Tuesday, Syndax Pharmaceuticals stock opened at $26.4 and closed at $27.2, up by 2.9% from the previous closing price of 26.5. The company’s stock price has been volatile in recent weeks and investors are uncertain about the future of Syndax Pharmaceuticals. Despite the losses, some analysts remain optimistic about the company’s potential as they believe that its new products and services could turn things around in the near future.

However, investors should keep an eye on the stock and remain cautious when investing in Syndax Pharmaceuticals. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Syndax Pharmaceuticals. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Syndax Pharmaceuticals. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Syndax Pharmaceuticals. More…

Key Ratios Snapshot

Some of the financial key ratios for Syndax Pharmaceuticals are shown below. More…

VI Analysis – Syndax Pharmaceuticals Intrinsic Stock Value

Through the use of the VI app, a comprehensive and simple analysis of the company has been made. The fair value of the company’s share is estimated to be around $421.9, as indicated by the VI Line. Currently, SYNDAX PHARMACEUTICALS stock is traded at $27.2, which is undervalued by a staggering 94%. This indicates that there is a potential for investors to earn attractive returns if they purchase the stock at its current price. The company has a strong balance sheet and its performance has been fairly consistent over the years. Furthermore, its cash flow from operations has been on the rise, indicating that it is in a good financial position. The management team is experienced and knowledgeable, and has demonstrated their ability to take the company in the right direction. For an investor, SYNDAX PHARMACEUTICALS presents an opportunity to benefit from its current undervalued price. Although there is no guarantee of returns, the company’s fundamentals suggest that it has the potential for significant growth in the future. Therefore, it is worth considering investing in the company while it is still trading at a discount. More…

VI Peers

The biopharmaceutical industry is highly competitive, with companies vying for market share in the development and commercialization of innovative therapies. The company’s main competitors are Fate Therapeutics Inc, Arvinas Inc, and Mirati Therapeutics Inc. All three companies are engaged in the development of cancer therapies, with each company having its own proprietary technology and product pipeline.

– Fate Therapeutics Inc ($NASDAQ:FATE)

Fate Therapeutics is a biopharmaceutical company that develops immunotherapies for cancer and other diseases. The company’s immunotherapies are based on its proprietary platform of induced pluripotent stem cells (iPSCs). Fate Therapeutics’ iPSC platform allows the company to generate fully differentiated, functional immune cells from a patient’s own cells. These immune cells can then be used to treat the patient’s disease. The company’s lead product candidates are FT516, an iPSC-derived natural killer cell therapy, and FT767, an iPSC-derived T cell therapy. Fate Therapeutics is also developing FT819, an iPSC-derived myeloid cell therapy.

– Arvinas Inc ($NASDAQ:ARVN)

Arvinas Inc is a pharmaceutical company that focuses on the development of treatments for cancer and other diseases. The company has a market cap of 2.35B as of 2022 and a Return on Equity of -20.23%. Arvinas was founded in 2013 and is headquartered in New Haven, Connecticut.

– Mirati Therapeutics Inc ($NASDAQ:MRTX)

Mirati Therapeutics Inc is a biopharmaceutical company that focuses on the development of novel small molecule therapeutics to treat cancer. The company’s market cap as of 2022 is 3.7B and its ROE is -33.77%. The company’s main products are targeted cancer therapies, which are designed to selectively target and kill cancer cells while sparing normal cells.

Summary

Syndax Pharmaceuticals has seen a loss in their stock value despite the market gains. Investors should consider the current media sentiment which is mostly positive when deciding whether to invest in Syndax Pharmaceuticals. The company has been focusing on developing oncology treatments, and has a number of clinical trials being conducted on their drugs.

They have also received approval for a phase 1 trial in Japan and have other collaborations with companies such as Merck and Genentech, as well as a partnership with the National Cancer Institute. With the potential for their products to provide treatment for cancer, Syndax Pharmaceuticals could be a worthwhile investment for those looking to diversify their portfolio.